Skip to contentB
BioCardia, Inc.
B
BCDABioCardia, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$13.00K$13.00Kderived−87.7% vs Q4 2022 Net Income-$2.07M-$2.07MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCardia, Inc. · CIK 925741 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$2,084,000N/M Operating Cash Flowderived-$1,851,000N/M Free Cash Flowderived-$1,851,000N/M Margins · derivedOperating margin-16030.8%−13183.6 pt vs Q4 2022
Net margin-15938.5%−13081.9 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 27, 2024 · 87 d after period end